Preliminary study on quantitative proteomic analysis of differentially expressed proteins in HER-2 positive and negative breast cancer

Abstract

Abstract:ObjectiveTo seek differentially expressed proteins for human epithelial growth factor receptor2 (HER2) negative and positive breast carcinoma through establishing proteins profiles, and to provide new prognostic markers and therapeutic targets for patients with breast cancer. MethodsHER2 positive and negative breast cancer protein expression profiles were established using proteomic isobaric tags for relative and absolute quantitation (iTRAQ) technology. Differences of protein expression were identified and parts of differential expression proteins were analyzed by bioinformatics, including protein function annotation and GO classification analysis and Kyoto Encyclopedia of Gene and Genome (KEGG) pathway analysis. ResultsProteomic analysis of breast cancer tissue with identified HER2 positive and negative groups showed 4 999 differentially expressed proteins by iTRAQ. Based on the criteria of the ratio of HER2(+)/HER2(－)≥3, 119 upregulated proteins were identified in HER2 positive group. Based on the criteria of the ratio of HER2(+)/HER2(－)≤0.5, 47 downregulated proteins were identified in HER2 positive group. The results of GO analysis showed that the molecular function, biological process and cellular composition of differentially expressed proteins were complex between HER2 positive and negative breast cancer. There were differences in the distribution of upregulated proteins and downregulation of proteins. KEGG pathway analysis showed that differentially expressed proteins involved in 168 signal pathways. ConclusionThere are differentially expressed proteins between HER2 positive and negative breast cancer, which involve complex molecular function, biological process and signaling pathway.

Key words:Breast neoplasms,Receptor, epidermal growth factor,Proteomics,Computational biology

Li Jing, Huang Sanqian, Ouyang Quchang, Zhong Jingmin, Gao Nina, Liu Liping, Liu Zhihong, Zeng Liang. Preliminary study on quantitative proteomic analysis of differentially expressed proteins in HER-2 positive and negative breast cancer[J]. Journal of International Oncology, 2016, 43(10): 721-727.

References

［1］ Chen W, Zheng R, Zuo T, et al. National cancer incidence and mortality in China, 2012［J］. Chin J Cancer Res, 2016, 28(1): 1-11. DOI: 10.3978/j.issn.10009604.2016.02.08. ［2］ Zhao X, Rdland EA, Tibshirani R, et al. Molecular subtyping for clinically defined breast cancer subgroups［J］. Breast Cancer Res, 2015, 17: 29. DOI: 10.1186/s1305801505204. ［3］ Kogawa T, Fouad TM, Liu DD, et al. High HER2/centromeric probe for chromosome 17 fluorescence in situ hybridization ratio predicts pathologic complete response and survival putcome in patients receiving neoadjuvant systemic therapy with trastuzumab for HER2overexpressing locally advanced breast cancer［J］. Oncologist, 2016, 21(1): 21-27. DOI: 10.1634/theoncologist.20150101. ［4］ Guo W, Wang W, Zhu Y, et al. HER2 status in molecular apocrine breast cancer: associations with clinical, pathological, and molecular features［J］. Int J Clin Exp Pathol, 2015, 8(7): 8008-8017. ［5］ Salim DK, Mutlu H, Eryilmaz MK, et al. Molecular types and neoadjuvant chemotherapy in patients with breast cancerwhile molecular shifting is more common in luminal a tumors, the pathologic complete response is most frequently observed in her2 like tumors［J］. Asian Pac J Cancer Prev, 2014, 15(21): 9379-9383. ［6］ Babyshkina N, Malinovskaya E, Patalyak S, et al. Neoadjuvant chemotherapy for different molecular breast cancer subtypes: a retrospective study in Russian population［J］. Med Oncol, 2014, 31(9): 165. DOI: 10.1007/s1203201401657. ［7］ Wong DJ, Hurvitz SA. Recent advances in the development of antiHER2 antibodies and antibodydrug conjugates［J］. Ann Transl Med, 2014, 2(12): 122. DOI: 10.3978/j.issn.23055839.2014.08.13. ［8］ Sotelo MJ, GarcíaSáenz JA, Manso L, et al. Lapatinib plus trastuzumab in pretreated human epidermal growth factor receptor 2positive metastatic breast cancer［J］. J Cancer Res Ther, 2014, 10(4): 967-972. DOI: 10.4103/09731482.138017. ［9］ Goel S, Wang Q, Watt AC, et al. Overcoming therapeutic resistance in HER2positive breast cancers with CDK4/6 inhibitors［J］. Cancer Cell, 2016, 29(3): 255-269. DOI: 10.1016/j.ccell.2016.02.006. ［10］ Jia WJ, Jia HX, Feng HY, et al. HER2enriched tumors have the highest risk of local recurrence in Chinese patients treated with breast conservation therapy［J］. Asian Pac J Cancer Prev, 2014, 15(1): 315-320. ［11］ Fan YS, Casas CE, Peng J, et al. HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline［J］. Breast Cancer Res Treat, 2016, 155(3): 457-462. DOI: 10.1007/s105490163717z. ［12］ CalderónGonzález KG, Valero Rustarazo ML, LabraBarrios ML, et al. Determination of the protein expression profiles of breast cancer cell lines by quantitative proteomics using iTRAQ labelling and tandem mass spectrometry［J］. J Proteomics, 2015, 124: 50-78. DOI: 10.1016/j.jprot.2015.04.018. ［13］ Chang HY, Li MH, Huang TC, et al. Quantitative proteomics reveals middle infrared radiationinterfered networks in breast cancer cells［J］. J Proteome Res, 2015, 14(2): 1250-1262. DOI: 10.1021/pr5011873. ［14］ Campone M, Valo I, Jézéquel P, et al. Prediction of recurrence and survival for triplenegative breast cancer (TNBC) by a protein signature in tissue samples［J］. Mol Cell Proteomics, 2015, 14(11): 2936-2946. DOI: 10.1074/mcp.M115.048967.

[1]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[2]	Sa Qiang, Xu Hangcheng, Wang Jiayu.Advances in immunotherapy for breast cancer[J]. Journal of International Oncology, 2024, 51(4): 227-234.
[3]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong.Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer[J]. Journal of International Oncology, 2024, 51(4): 235-238.
[4]	Chen Boguang, Wang Sugui, Zhang Yongjie.Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer[J]. Journal of International Oncology, 2024, 51(2): 73-82.
[5]	Gu Huayan, Zhu Teng, Guo Guilong.Breast microbiota and breast cancer： present and future[J]. Journal of International Oncology, 2024, 51(1): 55-58.
[6]	Wang Jing, Xu Wenting.Value of NLR， CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm[J]. Journal of International Oncology, 2023, 50(9): 520-526.
[7]	Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying.Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients[J]. Journal of International Oncology, 2023, 50(9): 527-531.
[8]	Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng.Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway[J]. Journal of International Oncology, 2023, 50(8): 449-456.
[9]	Pan Shulan, Liu Chang, He Ping.Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer[J]. Journal of International Oncology, 2023, 50(8): 457-462.
[10]	Wang Wende, Zeng De.Research progress on the mechanism of endocrine therapy resistance for breast cancer[J]. Journal of International Oncology, 2023, 50(6): 352-356.
[11]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai.Research progress on the application of combining radiotherapy and systemic therapy in breast cancer[J]. Journal of International Oncology, 2023, 50(6): 362-367.
[12]	Zhu Jun, Huang Meijin, Li Yuan, Liu Zegang, Xun Xin, Chen Hong.Research progress on targeted therapy of breast cancer with low expression of HER2[J]. Journal of International Oncology, 2023, 50(4): 236-240.
[13]	Zhou Ting, Xu Shaohua, Mei Lin.Efficacy and safety of bevacizumab combined with capecitabine in the treatment of advanced breast cancer[J]. Journal of International Oncology, 2023, 50(3): 144-149.
[14]	Li Lixi, Zhang Di, Luo Yang, Ma Fei.Clinical application of PARP inhibitors in breast cancer[J]. Journal of International Oncology, 2023, 50(2): 91-96.
[15]	Geng Rui, Ma Junqiang, Guo Qiang, Niu Zhaofeng.Tendency of elderly patients with breast cancer to choose comprehensive treatment mode and its influencing factors[J]. Journal of International Oncology, 2023, 50(11): 650-654.